Evidence map›Paper›PMID 39830033›Full record

ArticleInfection and drug resistance2025

In vitro Antibacterial Effect of Reduning Combined with Polymyxin on Carbapenem Resistant

Zui-Fei Shangguan, Hong-Lei Chen, Yi-Fan Li, Na Shi, Qi-Fen Mao

Abstract read
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zui-Fei ShangguanDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310006, People's Republic of China.
Hong-Lei ChenDepartment of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, 310012, People's Republic of China.
Yi-Fan LiCollege of Laboratory Medicine and College of Bioengineering, Hangzhou Medical University, Hangzhou, Zhejiang, 311399, People's Republic of China.
Na ShiMedical Laboratory, Second Sanatorium of Air Force Healthcare Center for Special Services, Hangzhou, Zhejiang, 310007, People's Republic of China.
Qi-Fen MaoDepartment of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, 310012, People's Republic of China.ORCID 0000-0002-2482-7059

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the status of carbapenem-resistant strains of Methods: A total of 50 different isolates of CRKP were collected, and the minimum inhibitory concentrations (MIC) of polymyxin, Reduning and polymyxin plus Reduning were measured with microbroth dilution method. Then, the fractional inhibition concentration index (FICI) was calculated. Results: A total of 50 strains of CRKP were isolated, sputum and clean urine were the most common source of CRKP, and intensive care unit was the most common source department. More than 90% of CRKP strains were resistant to cefepime, ceftazidime, piperacillin/tazobactam, and cefoperazone/sulbactam. The rate of resistance to levofloxacin was high, but that to tobramycin, tigecycline, and compound sulfamethoxazole was low. In addition, MIC of Reduning plus polymyxin for CRKP was lower than that of Reduning or polymyxin alone. Among 50 strains of CRKP, FICI ≤0.5 was noted in 7 strains, 0.5 < FICI ≤ 1.0 in 43 strains, and none had FICI >1.0. The results showed Reduning combined with polymyxin B exerted additive effect on CRKP and conferred synergistic effect on several strains of CRKP. Conclusion: Reduning has antibacterial effect on CRKP in vitro, and the addition of Reduning can reduce the dose of polymyxin in the treatment of CRKP.

Indexed as

Carbapenem resistant Klebsiella pneumoniaein vitro antibacterial activitypolymyxinReduning

Identifiers

PMID39830033
PMCPMC11740547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.